We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$224K
AUM Growth
-$183M
Cap. Flow
+$30.6M
Cap. Flow %
13,629.74%
Top 10 Hldgs %
33.66%
Holding
127
New
36
Increased
38
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.26M
2
MGNX icon
MacroGenics
MGNX
+$5.18M
3
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.94M
4
VCYT icon
Veracyte
VCYT
+$3.89M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$3.65M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.78M
2
CRIS icon
Curis
CRIS
+$4.17M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.01M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.36M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.44%
2 Financials 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
51
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.66K 0.74%
+15,000
New +$215K
COGT icon
52
Cogent Biosciences
COGT
$6.76B
$1.61K 0.72%
198,245
+78,245
+65% +$661K
BGMS
53
Bio Green Med Solution Inc
BGMS
$4.86M
$1.53K 0.68%
72
+3
+4% +$74.4K
MCRB icon
54
Seres Therapeutics
MCRB
$45M
$1.52K 0.68%
3,196
-1,804
-36% -$761K
RAPT
55
DELISTED
RAPT Therapeutics
RAPT
$1.5K 0.67%
+5,899
New +$1.1M
RLMD icon
56
Relmada Therapeutics
RLMD
$540M
$1.5K 0.67%
+46,729
New +$1.62M
ARNA
57
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.4K 0.63%
20,577
+577
+3% +$37.6K
PYPD icon
58
PolyPid
PYPD
$78.2M
$1.4K 0.62%
5,152
+158
+3% +$43.9K
DCPH
59
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.36K 0.61%
37,257
-2,508
-6% -$97.1K
CCXI
60
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$1.34K 0.6%
+100,000
New +$2.46M
RETA
61
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.32K 0.59%
+9,346
New +$1.06M
MREO
62
Mereo BioPharma
MREO
$48.9M
$1.29K 0.57%
405,871
+230,871
+132% +$775K
DCTH icon
63
Delcath Systems
DCTH
$400M
$1.25K 0.56%
99,189
+59,189
+148% +$679K
EVGN icon
64
Evogene
EVGN
$5.83M
$1.24K 0.55%
36,125
+1,125
+3% +$44.1K
LONA
65
LeonaBio Inc
LONA
$66.1M
$1.21K 0.54%
+11,798
New +$2.06M
TRIL
66
DELISTED
Trillium Therapeutics Inc.
TRIL
$923 0.41%
95,190
+35,190
+59% +$331K
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
$905 0.4%
5,732
+732
+15% +$109K
WVE icon
68
Wave Life Sciences
WVE
$1.12B
$826 0.37%
123,972
+83,972
+210% +$549K
AKRO
69
DELISTED
Akero Therapeutics
AKRO
$819 0.37%
33,028
+1,028
+3% +$28.9K
ARDX icon
70
Ardelyx
ARDX
$1.24B
$752 0.34%
99,237
+54,237
+121% +$401K
ASND icon
71
Ascendis Pharma A/S
ASND
$16.5B
$737 0.33%
5,599
-13,095
-70% -$1.74M
SURF
72
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$705 0.31%
94,539
-5,461
-5% -$42.1K
BLU
73
DELISTED
BELLUS Health Inc.
BLU
$653 0.29%
+209,933
New +$802K
ODT
74
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$652 0.29%
186,680
-313,320
-63% -$1.08M
VRAY
75
DELISTED
ViewRay, Inc.
VRAY
$623 0.28%
+94,388
New +$503K
1 2
3
4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Silverarc Capital Management held 127 positions worth $224K, down 100% from $183M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Silverarc Capital Management deployed $30.6M of net new capital in Q2 2021, opening 36 new positions and adding to 38 existing holdings. Its largest new stake was MacroGenics: 176,915 shares worth $4.75K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Curis, an estimated $4.17M trimmed.

  • Silverarc Capital Management's largest Q2 2021 buy was MacroGenics: 176,915 shares worth $4.75K.
  • Silverarc Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.26M increase.
  • Silverarc Capital Management's biggest Q2 2021 reduction was Curis, cutting an estimated $4.17M.
  • Silverarc Capital Management fully exited Vericel Corp in Q2 2021, selling an estimated $6.78M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $224K portfolio in Q2 2021.
  • Silverarc Capital Management opened 36 new positions and closed 31 in Q2 2021.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $224K.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.